Skip to content

Assessment of the Durability of Cardioneuroablation Using Physiological Indices of Heart Rate Reactivity

Assessment of the Durability and Clinical Effectiveness of Parasympathetic Denervation Following Cardioneuroablation Using Physiological Indices of Heart Rate Reactivity

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06697145
Enrollment
12
Registered
2024-11-20
Start date
2021-11-23
Completion date
2024-12-31
Last updated
2025-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Syncope, Vasovagal, Neurally-Mediated

Brief summary

Cardioneuroablation is a novel treatment option for reflex-mediated syncope. It involves thermal destruction of neural tissue in the close proximity of heart using catheter introduced to the heart through vein in the groin. Effectiveness of the procedure is satisfactory, however, in some cases there is a possibility of the re-growth of previously ablated tissue. We aim to investigate whether this process could be traced by measurement of various physiological parameters related to heart rate reactivity. Additionally we intend to reveal whether changes in those parameters over time could influence clinical effeciveness of the procedure.

Interventions

Ablation of parasympathetic ganglia of the heart

Sponsors

Wroclaw Medical University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* signed informed consent * sinus rhythm * clinical indications for cardioneuroablation for the treatment of vagally-mediated syncope

Exclusion criteria

* pregnancy * known atropine hypersensitivity

Design outcomes

Primary

MeasureTime frame
Change in degree of parasympathetic denervation (%)12 months

Secondary

MeasureTime frame
Change in heart rate (beats/min)12 months
Change in heart rate variability (ms)12 months
Change in cardiac barosensitivity (ms/mmHg)12 months
Change in hypoxic heart rate response (beats/min SpO2)12 months
Time to recurrence of syncopal event (days12 months

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026